MIRM — Mirum Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1759425 ·
Last close
$91.95
Market Cap
$6.00B
52W High
$130.00
52W Low
$63.23
ADV30
664,039
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 185,721,000 150,549,000 -46,246,000 -40,766,000 1,026,613,000 243,188,000 1,080,799,000
Jun 2026 176,243,000 145,895,000 -26,102,000 -67,227,000 1,044,981,000 330,728,000 1,055,403,000
Mar 2026 159,882,000 131,077,000 -63,163,000 -790,155,000 890,916,000 324,907,000 648,422,000
Dec 2025 148,932,000 120,668,000 -4,567,000 -5,730,000 842,813,000 296,683,000 528,123,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-271,259,000
Investing CF
$-199,422,000
Financing CF
$436,173,000
CapEx
$-37,592,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-15.47
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,565,692,000
Inventory
$25,486,000
Receivables
$156,348,000
ST Investments
$130,499,000
EBIT TTM
$-888,971,000
Pretax Income TTM
$-900,409,000
Interest Exp TTM
$11,438,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$670,777,984
EBITDA
$-118,305,000
Free Cash Flow
$98,386,496
Enterprise Value
$6,488,108,032
Total Cash
$373,687,008
Total Debt
$743,561,984
Shares Out
65,282,044
Trailing EPS
$-14.47
Book Value
$-0.83
ROE
-760.0%
ROA
-10.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 521,312,000 -22,136,000 -23,363,000 842,813,000 528,123,000 314,690,000 55,827,000
Dec 2024 336,888,000 -87,606,000 -87,942,000 670,754,000 445,114,000 225,640,000 10,325,000
Dec 2023 186,374,000 -109,154,000 -163,415,000 646,621,000 397,951,000 248,670,000 -70,944,000
Dec 2022 77,062,000 -131,220,000 -135,665,000 352,906,000 210,869,000 142,037,000 -120,136,000

TTM Snapshot

Revenues TTM
$618,067,000
NetIncome TTM
$-860,207,000
OpCashFlow TTM
—
Assets (Latest)
$1,044,981,000
Forward EPS
$0.32

Max Pain — expiry 2026-12-18

max pain strike: $85.00 · spot: $92.49 · call oi: 1,310 · put oi: 496
Expected Move to 2026-12-18: ±$9.40 (10.16%) — implied range $83.09 – $101.89 · ATM straddle on $90.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ARWR ARROWHEAD PHARMACEUTICALS, INC. $6.08B $42.99 —
LGND LIGAND PHARMACEUTICALS INC $5.86B $293.81 —
BLTE BELITE BIO, INC $6.35B $157.72 —
ORKA Oruka Therapeutics, Inc. $6.53B $96.32 —
GIFLF Grifols SA $5.37B $12.72 —

News headlines (Yahoo Finance, 1h cache)

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-12 21:01 · Yahoo
Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD
2026-11-10 12:30 · Yahoo
No Cost Exome Testing Could Be A Game Changer For GeneDx (WGS)
2026-11-07 10:16 · Yahoo
GeneDx and Mirum to provide genetic tests for cholestasis, cataracts or PBD-ZSD
2026-11-06 11:03 · Yahoo
GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
2026-11-05 13:30 · Yahoo
Why Mirum Pharmaceuticals (MIRM) Is Up 11.4% And What's Next After Earnings Beat
2026-11-05 04:42 · Yahoo
Mirum (MIRM) Q3 2026 Earnings Call Transcript
2026-11-04 15:29 · Yahoo
Mirum Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-04 13:30 · Yahoo
Mirum Pharmaceuticals Q3 Earnings Call Highlights
2026-11-04 02:14 · Yahoo
Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings
2026-11-03 21:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.